bisoprolol sold brand name zebeta among others beta blocker medication used heart includes tachyarrhythmias high blood pressure chest pain enough blood flow heart heart taken common side effects include headache feeling tired diarrhea swelling severe side effects include worsening asthma blocking ability recognize low blood sugar worsening heart concerns use pregnancy may harmful bisoprolol beta blocker family medications selective bisoprolol world health organizations list essential bisoprolol available generic commonly prescribed medication united states million bisoprolol currently used prevention cardiovascular events following heart attack patients risk factors disease management congestive heart failure reduced ejection secondline agent bisoprolol may beneficial treatment high blood pressure recommended firstline antihypertensive agent adjunct firstline antihypertensive agents patients accompanying comorbidities example congestive heart failure selected beta blockers added patients remain mildly moderately symptomatic despite appropriate doses angiotensinconvertingenzyme inhibitor cardiac ischemia drug used reduce activity heart muscle thereby reducing oxygen nutrient demands allowing reduced blood supply still transport sufficient amounts oxygen nutrients meet overdose bisoprolol lead fatigue bronchospasms bronchospasms hypoglycemia occur high doses drug antagonist adrenergic receptors located lungs liver bronchospasm occurs due blockage receptors lungs hypoglycemia occurs due decreased stimulation glycogenolysis gluconeogenesis liver via reported cases clinically evident druginduced liver injury associated nonselective betablockers avoided people asthma bronchospasm may cause exacerbations worsening selective betablockers like bisoprolol shown cause increase asthma may cautiously tried controlled mildtomoderate asthma cardiac comorbidities metaanalysis found unlike nonselective betablockers selective betablockers bisoprolol showed small impact lung function patients remaining responsive salbutamol agonist rescue therapy endorses use bisoprolol select patients controlled supported clinical trial bisoprolol significant impact bronchodilation post salbutamol administration bisoprolol cardioprotective selectively competitively blocks catecholamine adrenaline stimulation adrenergic receptors adrenoreceptors mainly found heart muscle cells heart conduction tissue cardiospecific also found juxtaglomerular cells normally adrenaline noradrenaline stimulation adrenoreceptor activates signalling cascade gs protein camp ultimately leads increased myocardial contractility increased heart rate heart muscle heart pacemaker bisoprolol competitively blocks activation cascade decreases adrenergic tonestimulation heart muscle pacemaker cells decreased adrenergic tone shows less contractility heart muscle lowered heart rate bisoprolol especially important comparison nonselective beta blockers effects drug limited areas containing adrenoreceptors mainly heart part bisoprolol whilst adrenoceptor selective help patients avoid certain sideeffects associated nonselective betablocker additional adrenoceptors signify superiority treating betablocker indicated cardiac conditions heart failure could prove beneficial patients specific bisoprolol higher degree compared atenolol metoprolol selectivity ranging times selective however nebivolol approximately times bisoprolol inhibits renin secretion tachycardia ingestion bisoprolol absorbed high bioavailability approximately plasma halflife eliminated body evenly distributes kidney excretion liver biotransformation bisoprolol lipid watersoluble classified beta blocker moderate lipophilicity hence intermediate potential crossing turn may result fewer effects central nervous system well lower risk neuropsychiatric side effects highly lipophilic beta blockers like propranolol greater effects beta blockers low lipophilicity like plasma protein binding bisoprolol approximately volume distribution lkg total clearance approximately lh bisoprolol eliminated body two ways substance converted liver inactive metabolites excreted kidneys remaining eliminated unchanged via since elimination equal liver kidney dose adjustment required patients hepatic renal impairment pharmacokinetics bisoprolol linear independent patients chronic heart failure plasma level bisoprolol higher halflife longer healthy subjects compared across studies currently lack evidence directly comparing bisoprolol pharmacokinetics healthy subjects chronic heart failure bisoprolol patented approved medical use approved medical use united states india sold trade name bisotab available strengths mg italy sold trade name congescor available strengths mg mg mg mg mg mg germany eastern europe bisoprolol marketed bisoprololratiopharm ratiopharm teva concor cor httpsenwikipediaorgwikibisoprolol